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Relatively little is known about frequency and extent of respiratory problems in 
sporadic inclusion body myositis (IBM). To address this issue a study of peripheral 
muscle and respiratory function and related symptoms was performed in a cohort 
with biopsy-proven IBM.  Dyspnoea, daytime sleepiness, dysphagia, spirometry, 
respiratory muscle strength, arterial blood gas tensions and ventilation during sleep 
were assessed. Sixteen patients were studied (10 males; age 68.1±9.9 years; 
disease duration 11.9±5.0 years; body mass index 28.5±4.0 kg/m2).  Four reported 
excessive daytime sleepiness; 8 had at least mild dysphagia; forced vital capacity 
was <80% predicted normal in 7; sniff nasal inspiratory pressure was reduced in 3; 
daytime hypoxemia was present in 9 and hypercapnia in one. Sleep study was 
performed in 15 and revealed sleep disordered breathing (apnoea-hypopnoea index 
23.4±12.8 (range 7-50.3) events/hr) in all. There were no consistent relationships 
between respiratory function impairment, occurrence of sleep disordered breathing, 
and severity of peripheral muscle weakness. Thus, asymptomatic impairment of 
respiratory function was common and sleep disordered breathing observed in all 
patients tested, irrespective of daytime respiratory function. This suggests respiratory 
function testing, including sleep study, should be performed routinely in IBM, 
irrespective of peripheral muscle function or other disease severity parameters. 
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1. INTRODUCTION  
 
The idiopathic inflammatory myopathies are a heterogeneous group of disorders 
which differ in their clinical, immunopathological features and diagnostic criteria.[1] 
The three most common forms are dermatomyositis, polymyositis, and inclusion body 
myositis (IBM) which is the most common acquired muscle disease in older 
individuals.[2] Several studies have addressed the ocurrence of respiratory 
complications in dermatomyositis and polymyositis, revealing a high prevalence of 
problems, including interstitial lung disease, hypercapnic respiratory failure due to 
muscle weakness, and obstructive sleep apnea.[3 4]  Much less is known about 
respiratory problems in IBM but case reports of respiratory failure in IBM patients 
support the hypothesis of possible respiratory muscle involvement.[5-8] However, 
these reports provide no guidance regarding the prevalence of respiratory problems 
in IBM.  Furthermore they have used a variety of measures of wakeful respiratory 
function, with no attempt to relate these to peripheral muscle function or to breathing 
during sleep.  These are significant deficiencies, as muscles are not uniformly 
affected in IBM, and where respiratory muscles or pharyngeal muscles are involved, 
sleep can be a vulnerable state because of the risk of sleep related hypoventilation or 
upper airway obstruction (i.e. obstructive sleep apnoea (OSA)).  Sleep-related 
reduction in ventilatory drive is associated with nocturnal hypoventilation in patients 
with moderate respiratory muscle weakness who may not yet have developed 
wakeful respiratory failure.  Thus, sleep hypoventilation can be a harbinger of 
respiratory failure in neuromuscular disorders in which the respiratory muscles are 
involved.[9]  It is known that OSA is common in disorders associated with pharyngeal 
muscle weakness.[10]  IBM is such a condition and a recent study suggests that it 




To better characterise these issues we used a standard array of tests to measure 
wakeful respiratory function, as well as ventilation during sleep, in a cohort of 16 
patients with proven inclusion body myositis.  Our purpose was to determine the 
frequency of respiratory muscle weakness, how this is related to peripheral muscle 
strength, and its impact on wakeful and sleep-related breathing function.  We 
hypothesised that deficits would be found and that the impacts would be more 
sensitively reflected in sleep-related than wakeful measures of breathing function. 
 
2. MATERIALS AND METHODS 
 
2.1. Subjects 
A cross-sectional study was performed of all consenting biopsy-proven IBM patients 
currently attending the clinics at the Australian Neuromuscular Research Institute 
(Perth, Western Australia).  Sixteen patients who fulfilled the Griggs et al  diagnostic  
criteria[12] for definite IBM were included (10 male; mean(±SD) age 68.1±9.9 years). 
Current smokers were excluded. None of the patients used oxygen therapy. Ten 
patients were on immunosuppressive treatment (5 prednisolone + methotrexate; 2 
prednisolone + mycophenolate; 2 methotrexate; 1 azathioprine). The study protocol 




Anthropometric data (age, gender, height, weight) were collected. Disease severity 
was assessed by the IBM functional rating scale (IBM-FRS).[13]  This scale 
assesses function across 10 activities of daily living scoring each from 0 (unable to 
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perform) to 4 (normal).  The closer the total score is to the maximum possible of 40 
the better the functional status of the patient. The strength in the quadriceps and 
other upper and lower limb muscles was evaluated by manual muscle testing (MMT) 
using a 0-10 point modification of the Medical Research Council (MRC) scale for 
muscle strength, which grades it from 0 (no movement detected) to 10 (normal).[14] 
The degree of breathlessness and its relationship to activity was assessed using the 
MRC Dyspnoea Scale which is a 5 point scale from 1 (breathless only with strenuous 
exercise) to 5 (too breathless to leave house).[15]  The degree of daytime sleepiness 
was assessed using the Epworth Sleepiness Scale (ESS), which questions likelihood 
of dozing from 0 (no chance) to 3 (high chance) under 8 different situations.[16] The 
closer to the maximum score of 24 the greater the degree of daytime sleepiness. The 
presence and severity of dysphagia was quantified using the Dysphagia Outcome 
and Severity Scale (DOSS), a 7 level scale from 1 (severe dysphagia) to 7 (normal in 
all situations).[17]  
 
Spirometry (FEV1, FVC and FEV1/FVC) was performed (EasyOne® Plus 
Spirometer, NDD Medical Technologies Inc., Andover MA) in both sitting and supine 
positions according to the standards of the American Thoracic Society.[18] 
Inspiratory muscle strength was evaluated using sniff nasal inspiratory pressure 
(SNIP) (MicroRPM, Carefusion Corporation, San Diego, CA). SNIP was measured 
according to the European Respiratory Society guidelines.[19 20]  
 
Gas exchange was assessed using arterialised capillary blood from the earlobe. 
Patients were all breathing room air (without oxygen supplementation) at the time of 
measurement.  The samples were analyzed (ABL700, Radiometer Medical ApS, 
Copenhagen, Denmark) for HCO3 concentration and partial pressures of oxygen 
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(PaO2) and carbon dioxide (PaCO2).  
 
Ventilation was studied during sleep using a dual channel (oximetry, nasal airflow) 
portable home monitoring device (ApneaLinkTM, Resmed Ltd, Bella Vista, Australia).   
The data was uploaded in European data format (EDF) into a laboratory 
polysomnographic analysis system (E series, Compumedics Ltd, Melbourne, 
Australia) for subsequent manual analysis to define: apnoea-hypopnoea index (AHI); 
arterial oxygen saturation (SpO2); oxygen desaturation index for number of 
desaturation events of 3% or more per hour of estimated sleep time (ODI-3%); and 
proportion of total sleep time spent at or below a saturation of 90% (TST≤90).  AHI 
was defined as the number of apnoeas (reductions in amplitude of nasal airflow to 
<10% of baseline for ≥10 seconds) and hypopnoeas (>50% reduction in nasal airflow 
from baseline (but not to a degree classifiable as an apnoea) or a lesser reduction in 
airflow associated with >3% oxygen desaturation with events lasting ≥10 seconds ) 
per hour of estimated sleep time.[21] 
  
Statistical analysis was performed with SPSS v15.0 software (IBM, Armonk, NY). 
Interrelationships between ventilatory capacity, gas exchange and polysomnographic 
parameters were examined using Pearson correlation coefficients and simple 
regression linear analysis. The Mann-Whitney U Test was used to compare the 
presence of sleep apnoea/hypopnoea events in patients with and without dysphagia 
and to assess differences between patients with and without immunosuppressive 
treatment. All results are presented as mean ± standard deviation. A p-value of <0.05 







Patient demographics, clinical data and results of measures of wakeful respiratory 
function, sleep breathing parameters and daytime capillary blood gas tensions are 
summarized in Table 1. Sixteen patients were studied. They were all the eligible 
patients registered at our clinic at commencement of data collection in February 
2013.  Complete data were collected on all patients apart from: (a) absent sleep data 
in patient 12; and (b) absent blood gas data and SNIP data in patient 13, because of 
logistical difficulties in each case. 
 
--Table 1 about here - 
 
3.1 Wakeful respiratory function 
None of the 16 subjects had any previously identified wakeful respiratory problems, 
apart from one with a history of asthma (subject 2).  She and two others (subjects 9 
and 11) had an FEV1/FVC ratio <70%, suggestive of airflow obstruction.  One of 
these (subject 9) had a previous 20-pack year smoking history. Six had a restrictive 
spirometric pattern (FVC <75% predicted value with normal or elevated FVC/FEV1 
ratio). None had evidence of paradoxical abdominal wall movement in the supine 
position, and only one (subject 10) had a fall in vital capacity of >8% with change 
from erect (seated) to supine posture.   
 
The SNIP was substantially reduced (<60 cm H2O) in 3 subjects (subjects 1, 3 and 
4), indicative of inspiratory muscle weakness. All these subjects had a restrictive 
ventilatory defect.  The subject with the lowest SNIP (subject 1) also had one of the 
lowest FVC and was the only one who was in type 2 (hypercapnic) respiratory failure 
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(PaCO2 >6 kPa).  Breathlessness was not prominent in any of the subjects.  No 
subject had an MRC dyspnoea score >2; half the subjects had a score of 1 and half 
of 2.  
 
3.2. Wakeful blood gases 
Wakeful capillary blood gases demonstrated hypoxemia (PaO2 <10.5 kPa) in 9 
patients and hypercapnia (PaCO2 >6 kPa) in one. While there were no significant 
correlations between blood gas parameters (PaO2, PaCO2, HCO3) and ventilatory 
capacity (FVC, FEV1), the patient with the lowest SNIP and near lowest FVC (subject 
1) was the only one with hypercapnia.  
 
3.3. Ventilation during Sleep  
Five patients (subjects 3, 4, 13, 15 and 16) reported regular snoring and two of them 
had previously diagnosed OSA. Four reported excessive daytime sleepiness 
(ESS≥10); mean ESS was 5.7±4.1 (range 0-12). None reported morning headache.  
 
Sleep studies were performed in 15 patients. During sleep, 10 patients demonstrated 
significant sleep hypoxemia (TST≤90 of ≥2%), with 6 having a nadir SpO2 below 
85%. Nocturnal desaturation episodes were very frequent (ODI-3% 18.2±8.4) 
events/hr). The mean AHI was 23.4±12.8 events/hr. All patients had sleep apnoea 
(AHI ≥5 events/hr), but with different severity grades: mild (AHI 5-15 events/hr) in 5, 
moderate (AHI 15-30 events/hr) in 6 and severe (AHI >30 events/hr) in 4. ODI and 
AHI were highly correlated (r=0.9, p<0.01). Daytime PaO2 was significantly correlated 
with the TST≤90 (r = -0.55, p = 0.43). We found no significant correlation between 
sleep oxygenation (TST≤90) and ventilatory capacity or BMI. The AHI was not 




The ESS score was significantly correlated with ODI (r = 0.66, p = 0.01), AHI (r = 
0.63, p = 0.01) and negatively correlated with FVC (r = -0.62, p = 0.01) and FEV1 (r = 
-0.58, p = 0.02).  
 
3.4. IBM Functional Rating Scale, quadriceps strength and other parameters 
Functional status (IBM-FRS) varied considerably between subjects. There were no 
correlations between disease duration and the IBM-FRS score, vital capacity, 
parameters of gas exchange or sleep ventilation, but quadriceps muscle strength 
was negatively correlated with disease duration (r = -0.70, p = 0.002). In terms of 
disease severity, the only correlations found were negative relationships between 
SNIP and both IBM-FRS (r = -0.66, p = 0.008) and quadriceps muscle strength (r = -
0.49, p = 0.06) and a negative correlation between FEV1 and quadriceps muscle 
strength (r = -0.53, p = 0.04). We found no difference in results for the variables 
studied between patients with and without immunosuppressive treatment. 
 
3.5. Swallowing function 
Half of the subjects had at least mild impairment of swallowing (DOSS ≤5) and two 
had videofluoroscopically confirmed swallowing dysfunction.  Mean DOSS was 
5.5±1.5 (range 3-7). There was no significant relationship between DOSS and any of 




This study of an unselected cohort of patients with sporadic IBM identified a range of 
respiratory problems of varying severity, from trivial to highly clinically significant.  
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Although respiratory symptoms were not prominent in the group as a whole, one of 
the 16 patients was in overt type 2 respiratory failure and 7 had vital capacities of 
less than 75% predicted normal, suggesting that they had significant ventilatory 
impairment.  In many cases subtlety or absence of daytime symptoms made such 
issues difficult to identify clinically.  Of particular note was the finding of sleep 
disordered breathing in all 15 patients in whom sleep studies were performed. 
 
The high occurrence of sleep disordered breathing in this cohort is consistent with 
findings of a recent Italian study.[11] In that study a polysomnographic evaluation 
was used and demonstrated sleep disordered breathing in 7 of 12 patients in whom 
adequate data were obtained.  While a lower proportion of sleep disordered 
breathing than observed in our patients it was notable that in 6 of these 7 the events 
were predominantly obstructive; the seventh had a tracheotomy but had mild central 
sleep apnoea.   
 
The dual channel device used to assess breathing during sleep in the present study 
is limited in its capacity to distinguish obstructive (reduced flow, ongoing effort) from 
central (concordant reduction in flow and effort) breathing disturbances by its lack of 
an effort sensor. Nevertheless there were several features evident on breath-by-
breath analysis of the raw flow data recorded by the device that suggest sleep 
disordered breathing was predominantly obstructive in each of our subjects.  Flow 
limitation (flattening of the inspiratory flow profile) and/or snoring (detected from 
observation of a characteristic high frequency component of the inspiratory flow 
signal) were commonly observed in association with respiratory events in each 
subject. The snoring was sometimes observed during development of events and 
often during recovery breaths following them. The morphology of the flow changes 
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observed during a substantial majority of events also favoured obstruction with a 
progressive decrease in flow (to cessation in the case of apnoeas) followed by an 
abrupt resumption of flow on termination of the event. This was in contrast to 
waxing/waning flow patterns typically seen in periodic breathing or to prolonged 
periods of reduced respiratory flow (without flow limitation) seen in sleep 
hypoventilation. 
 
Sleep is associated with reduced skeletal muscle activation and ventilatory drive, 
physiological changes that make it a vulnerable state for patients with weak 
pharyngeal or respiratory muscles. Deficiencies in these muscles may become 
manifest during sleep as upper airway obstruction or hypoventilation, even if such 
impairments are insufficient to cause wakeful symptoms.[9] OSA can be relatively 
asymptomatic, particularly in its milder forms. Daytime sleepiness, a common 
symptom resulting from associated sleep disruption, is inconsistently present.  
Nevertheless, whether overtly symptomatic or not, OSA is associated with a range of 
co-morbidities that make it important to identify and treat.[22]  
 
A high occurrence of OSA in IBM might be expected given the frequent presence of 
overt or covert pharyngeal muscle weakness in these patients.[2] Although half of the 
patients in the present study also had dysphagia, the lack of a direct relationship 
between the DOSS and sleep disordered breathing severity suggests that wakeful 
pharyngeal muscle dysfunction is often subclinical and that the DOSS is insensitive 
to its presence. While 50% of the cohort had a DOSS of 5 or less, indicating at least 
moderate swallowing impairment, the findings of this study suggest that sleep-related 
pharyngeal muscle dysfunction, resulting in OSA, could be present in more, a 




Apart from pharyngeal muscle dysfunction, impaired respiratory muscle function was 
also commonly observed in this patient group.  While breathlessness was not a 
prominent feature in any of the patients, vital capacity was reduced (<75% of 
predicted normal) in 7 of them.  In one (subject 2), this could be attributed to smoking 
related airflow obstruction, as evidenced by her reduced FEV1/FVC ratio. In the 
remaining 6 patients it is likely that their low vital capacities were due to respiratory 
muscle weakness: in the 5 of them in whom SNIP was also measured it was found to 
be <80 cm H2O in each, while in 3 of these it was <60 cm H2O, which is below the 
accepted lower limit of normal for this test.[23]  
 
The finding of an inverse relationship between quadriceps muscle strength and both 
ventilatory capacity (FEV1) and inspiratory muscle strength, as reflected by SNIP, 
was unexpected and the possibility that this negative relationship may be factitious 
cannot be excluded, particularly given the relatively low number of patients studied. 
Nevertheless, it may serve to underline the heterogeneous nature of the muscle 
involvement in IBM and the absence of a fixed relationship between the degree of 
respiratory muscle weakness and limb muscle weakness. Similarly, there was a 
negative correlation between SNIP and IBM-FRS. These findings suggest that 
respiratory status of IBM patients cannot be inferred from peripheral muscle function 
or other non-respiratory disease severity parameters. They also raise the possibility 
that there may be adaptive changes in respiratory muscle function in the face of 
progressive weakness of the limb muscles and associated impairment of mobility and 




Only one patient (subject 1) was in overt type 2 respiratory failure, with a wakeful 
PaCO2 of 6.6 kPa and associated hypoxaemia (9.25 kPa).  In this patient the SNIP 
was the lowest observed in the cohort and FVC was almost the lowest, consistent 
with respiratory muscle weakness.   Despite this, breathlessness was not a feature in 
this patient, illustrating the covert nature of the respiratory problems.  Notably, neither 
this patient nor any of the others had a substantial (>10%) decrease in FVC between 
the upright and supine postures as is usually present with diaphragmatic 
weakness.[24] This suggests that any respiratory muscle weakness is largely due to 
weakness of rib cage and abdominal musculature rather than the diaphragm.  The 
other notable feature in Subject 1 was her high AHI, suggesting that she had 
substantial pharyngeal as well as respiratory muscle weakness.  Her reduced DOSS 
supports this contention.  The combination of OSA and respiratory muscle 
impairment is known to be potent in the pathogenesis of wakeful respiratory 
failure.[9]   
 
It is noteworthy that 8 of the other 15 subjects also had mild-to-moderate daytime 
hypoxemia (PaO2 from 7.9 to 10.1 kPa), but with normal PaCO2, suggesting that the 
reduced PaO2 is likely to be due to disordered gas exchange (e.g. from age-related 
changes or other factors such as obesity-related atelectasis) rather than alveolar 
hypoventilation.  While sleep hypoventilation is a possible explanation for the finding 
of high TST≤90 findings in some individuals, those with greatest TST≤90 (subjects 2, 
9 and 16) all had a wakeful PaO2 of <9 KPa and PaCO2 of ≤5.5 KPa, suggesting, in 
them at least, that nocturnal hypoxemia reflected disordered gas exchange that was 
also evident when awake. Indeed, the direct relationship we observed between 
daytime PaO2 and nocturnal TST≤90 may largely reflect different (wakeful and sleep-
related) measures of an independently determined gas exchange abnormality (eg 
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age related.[25 26])  However, it also raises the possibility that sleep hypoxemia 
could  be making a direct contribution to the daytime hypoxemia.[27]   
 
We found no significant differences in any of the parameters studied between 
patients with and without immunosuppressive treatment. This suggests that the 
changes in respiratory function observed in the present study cannot be simply 
explained by chronic utilization of corticosteroids or other immunosuppressive drugs.   
Nevertheless these findings do not exclude the possibility of respiratory effects from 
such drugs in other patients and/or changes in other more complex respiratory 
assessments, such as high-resolution imaging or gas transfer factor, not assessed 
here.   
 
This study has limitations. Firstly there was the relatively low number of patients 
enrolled, which reflects the low prevalence of IBM in the general population.  A 
survey in 2008 in Western Australia, the setting of the present study, reported a 
prevalence of 14.9 cases per million population.[28] Nevertheless the present cohort 
was unselected, representing all eligible patients attending a large clinic specializing 
in neuromuscular disorders. This limited the capacity to draw inferences from this 
descriptive study. Secondly, the dual channel (oximetry, respiratory flow) 
ApneaLinkTM device provides a limited assessment of sleep disordered breathing as 
lack of an effort sensor reduces the capacity to distinguish central from obstructive 
events and lack of sleep staging (as provided for by gold standard polysomnography) 






The high frequency of pharyngeal and respiratory muscle involvement in this patient 
cohort, and the frequently subclinical nature of these problems, suggests that they 
should be specifically looked for in all cases of IBM. Investigations during sleep are 
particularly important where potential pharyngeal or respiratory muscle impairment is 
concerned, as mild dysfunction may only be apparent in the presence of sleep 
related reductions in muscle activation and ventilatory drive. Sleep disordered 
breathing, which was observed in all the patients tested and was often severe, is 
amenable to treatment by both ensuring potential aggravating factors such as alcohol 
and drug consumption and weight excess are addressed and, commonly, use of 
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Table 1.   Demographic, Clinical, Respiratory and Sleep Data from the 16 Subjects  
 
BMI = body mass index; MRC Dyspnoea = Medical Research Council dyspnoea scale; ESS = Epworth Sleepiness Scale; DOSS = Dysphagia Outcome 
and Severity Scale; MMT = Manual Muscle Testing score for quadriceps strength on 10-point scale (average of right and left sides); IBM-FRS = inclusion 
body myositis functional rating scale (maximum score 40); CK = creatine kinase; SNIP = sniff inspiratory pressure; AHI = apnoea-hypopnoea index; 
TST≤90 = % total sleep time spent at or below a SpO2 <90%.  For further explanations see text. 
 
















































1 68 F 30.1 8 2 8 3 7.5 28 179 47 61 81.9 0 35.7 94 5 6.6 9.25 30 
2 63 F 32 9 2 7 7 6.5 26 1262 81 70 60.7 5 28.7 90 20 5.5 8.8 27 
3 76 F 25.5 14 2 7 7 4.5 37 36 58 57 87.4 0 31.6 93 0 4.9 10.0 24.1 
4 79 M 28.1 4 2 4 7 6.5 32 163 57 73 73 2 20 93 0 4.0 15.2 21.2 
5 74 M 32.7 6 1 10 5 8 19 238 79 66 74.9 0 12.6 93 2 5.1 11.7 23.4 
6 72 F 25.8 14 1 3 7 2 18 170 96 89 74.6 7 8.1 96 0 5.0 9.75 25.1 
7 71 M 32.7 14 1 12 7 2.5 26 399 76 73 73.9 0 50.3 94 3 4.4 11.1 23.2 
8 64 M 36.9 16 2 1 5 3.5 21 132 88 97 78.9 0 20.9 94 2 3.4 11.8 16.8 
9 67 F 24.1 6 2 1 4.5 9 29 75 70 104 67 3 14.3 92 10 4.8 8.5 23.6 
10 73 M 29.6 17 1 12 4.5 2 25 56 92 89 77.1 9 41.3 93 6 5.7 9.3 26 
11 78 M 27.7 7 1 6 7 2 31 191 91 97 61.6 2 15.9 92 6 4.75 10.85 23.6 
12 66 F 24.5 11.5 2 5 3 5 33 112 60 90 78.3 0 - - - 4.8 9.1 24.6 
13 55 M 32 13 2 11 7 8 32 272 - 73 71.8 1 26.2 92 5.3 - - - 
14 40 M 25.7 12 1 2 6 4.5 26 220 73 97 80 0 7 95 0 5.2 10.1 24.6 
15 65 M 22.1 18 1 2 4 2 27 331 81 91 81 0 9.5 94 1 5.6 10.6 26.2 
16 78 M 26.9 22 1 0 4 1.5 32 666 64 91 73 0 28.6 91 9 5.5 7.9 25.7 
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Sleep Disordered Breathing and Subclinical Impairment of Respiratory Function are 
Common in Sporadic Inclusion Body Myositis 
• Asymptomatic respiratory impairment was common in inclusion body myositis 
(IBM).  
• In these patients with IBM sleep disordered breathing was ubiquitous. 
• Presence of these problems was not consistently related to duration or functional 
rating. 
• Respiratory function and sleep study should be performed routinely in IBM. 
 
 
